ClinicalTrials.gg

Program

INE963

Also written as “INE 963”.

In Novartis's pipeline, Plasmodium falciparum inhibitor. Its studies are mostly in Malaria, Falciparum, led by Novartis.

Furthest: phase 2, since Feb 17, 20234 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis41 open or runningphase 2since Feb 17, 2023May 12, 2021none ahead
  • Named in Novartis’s own pipeline as INE963, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 12, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT04896632 · 64 enrolled · United Kingdom
  2. Feb 17, 2023Phase 2 study in MalariaNCT05750628 · 327 planned · Burkina Faso, Côte d’Ivoire, Gabon and more
  3. Nov 14, 2025Phase 2 study in Malaria, FalciparumNCT07235020 · 52 enrolled · Burkina Faso, Côte d’Ivoire, Gabon and more
  4. Sep 4, 2026Phase 2 study in Malaria, FalciparumNCT07811882 · 95 enrolled · Burkina Faso, Côte d’Ivoire, Gabon and more

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Plasmodium falciparum inhibitor”the company's pipeline, read by Claude · source

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07811882Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more2CompletedJun 17, 202695
NCT07235020Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more2CompletedJan 30, 202552
NCT05750628Malaria · Burkina Faso, Côte d’Ivoire, Gabon and more2RecruitingJun 9, 2026327
NCT04896632Healthy Volunteers · United Kingdom1TerminatedNov 24, 202264

How it is read

Names in the registry

  • “INE963”, 3 entries
  • “INE 963”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.